Twin Capital Management Inc. Cuts Stake in Eli Lilly And Co (NYSE:LLY)

Twin Capital Management Inc. lowered its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 38.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 70,510 shares of the company’s stock after selling 44,340 shares during the quarter. Twin Capital Management Inc.’s holdings in Eli Lilly And Co were worth $7,812,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. Comerica Securities Inc. increased its holdings in shares of Eli Lilly And Co by 80.6% in the fourth quarter. Comerica Securities Inc. now owns 4,154 shares of the company’s stock valued at $481,000 after purchasing an additional 1,854 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Eli Lilly And Co by 0.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,070,587 shares of the company’s stock valued at $239,597,000 after purchasing an additional 18,958 shares during the last quarter. Farmers & Merchants Trust Co of Chambersburg PA increased its holdings in shares of Eli Lilly And Co by 23.6% in the first quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 834 shares of the company’s stock valued at $108,000 after purchasing an additional 159 shares during the last quarter. WP Advisors LLC acquired a new position in shares of Eli Lilly And Co in the first quarter valued at $38,000. Finally, Sciencast Management LP acquired a new position in shares of Eli Lilly And Co in the first quarter valued at about $536,000. Hedge funds and other institutional investors own 79.48% of the company’s stock.

Several equities analysts recently commented on LLY shares. BMO Capital Markets upped their price target on shares of Eli Lilly And Co from $130.00 to $133.00 and gave the company an “outperform” rating in a research note on Wednesday, May 1st. Edward Jones raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 price objective for the company in a research report on Tuesday, April 23rd. Zacks Investment Research cut shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, May 21st. TheStreet cut shares of Eli Lilly And Co from a “b+” rating to a “c+” rating in a research report on Thursday, May 9th. Finally, ValuEngine cut shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Friday, June 28th. Nine equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $123.49.



In related news, VP Michael J. Harrington sold 16,000 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $116.72, for a total value of $1,867,520.00. Following the completion of the transaction, the vice president now owns 110,300 shares in the company, valued at approximately $12,874,216. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Joshua L. Smiley acquired 426 shares of the company’s stock in a transaction that occurred on Wednesday, June 5th. The stock was acquired at an average price of $118.03 per share, with a total value of $50,280.78. Following the acquisition, the chief financial officer now owns 30,410 shares in the company, valued at $3,589,292.30. The disclosure for this purchase can be found here. 0.11% of the stock is currently owned by corporate insiders.

LLY traded down $0.20 on Thursday, hitting $110.09. 108,123 shares of the stock were exchanged, compared to its average volume of 3,974,435. Eli Lilly And Co has a 12 month low of $102.08 and a 12 month high of $132.13. The company has a 50-day moving average of $110.66. The company has a quick ratio of 0.87, a current ratio of 1.13 and a debt-to-equity ratio of 4.98. The firm has a market capitalization of $109.60 billion, a price-to-earnings ratio of 19.90, a price-to-earnings-growth ratio of 2.01 and a beta of 0.19.

Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Tuesday, July 30th. The company reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.45 by $0.05. The firm had revenue of $5.64 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Eli Lilly And Co had a net margin of 33.76% and a return on equity of 70.86%. The business’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.48 earnings per share. On average, equities analysts expect that Eli Lilly And Co will post 5.72 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be issued a $0.645 dividend. The ex-dividend date of this dividend is Wednesday, August 14th. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.34%. Eli Lilly And Co’s dividend payout ratio (DPR) is currently 46.49%.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: What are the advantages to having securities held in street name?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.